Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 15/20 | 0.55 |
| ▸ | MAOA | P21397 | 5/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4087489 | 1.00 | MAOB (0.55) | MAOBMAOAKCNH2MCHR1PARP10 | |
| SCHEMBL5570260 | 1.00 | MAOB (0.55) | MAOBMAOAKCNH2MCHR1PARP10 | |
| Hydrochloric Acid SCHEMBL5567223 | 0.99 | MAOB (0.56) | MAOBMAOAKCNH2MCHR1PARP10 | |
| Hydrochloric Acid SCHEMBL5566729 | 0.99 | MAOB (0.56) | MAOBMAOAKCNH2MCHR1PARP10 | |
| Hydrochloric Acid SCHEMBL5566724 | 0.99 | MAOB (0.56) | MAOBMAOAKCNH2MCHR1PARP10 | |
| SCHEMBL5567497 | 0.92 | MAOB (0.49) | MAOBMAOAKCNH2MCHR1PARP10 | |
| SCHEMBL3506566 | 0.85 | MAOB (0.59) | MAOBMAOAKCNH2PARP10 | |
| SCHEMBL3506564 | 0.85 | MAOB (0.59) | MAOBMAOAKCNH2PARP10 | |
| Hydrochloric Acid SCHEMBL5570296 | 0.85 | NPC1 (0.55) | MAOBKCNH2MCHR1PARP10 | |
| Hydrochloric Acid SCHEMBL5570291 | 0.85 | NPC1 (0.55) | MAOBKCNH2MCHR1PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235581-B2 | 4-pyrrolidino-phenyl-benzyl ether derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1542971-A1 | 4-PYRROLIDINO-PHENYL-BENZYL ETHER DERIVATIVES | F. Hoffmann-La Roche Ltd. (CH) | 2005-06-22 | — | — | EP | disclosed |
| US-20040097578-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-05-20 | — | — | US | disclosed |
| WO-2004026826-A1 | 4-PYRROLIDINO-PHENYL-BENZYL ETHER DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097578-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | MAOB, MAOA, COMT | MAOB 1/4885MAOA 2/4885KCNH2 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.